<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01804712</url>
  </required_header>
  <id_info>
    <org_study_id>121451</org_study_id>
    <nct_id>NCT01804712</nct_id>
  </id_info>
  <brief_title>Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy</brief_title>
  <official_title>A Pilot Study of Rituximab Neoadjuvant Therapy in Patients With High Risk Prostate Cancer Scheduled to Undergo Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stephen Howell, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is now substantial evidence that B cells are recruited into prostate cancers by CXCL13&#xD;
      released by the tumor cells. B cells release lymphotoxin which drives malignant cell&#xD;
      proliferation through the NFkB pathway. This is a pilot trial in 18 patients to determine&#xD;
      whether depletion of B cells by rituximab will result in a decrease in the extent of B cell&#xD;
      infiltration of the prostatic cancer. The extent of infiltration in the diagnostic biopsy&#xD;
      will be compared to that in the prostatectomy samples following administration of 4 weekly&#xD;
      doses of rituximab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, single institution, pilot study of rituximab neoadjuvant therapy in&#xD;
      patients with high risk prostate cancer scheduled to undergo radical prostatectomy. Prior to&#xD;
      prostatectomy, patients will receive one treatment cycle (28 days) of rituximab 375 mg/m2&#xD;
      intravenously once weekly. Patients will be scheduled to undergo radical prostatectomy within&#xD;
      two weeks of completing study treatment. Tissue from prostatectomy will be used for&#xD;
      immunohistochemistry (IHC) staining of pharmacodynamic markers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Histologic response rate after one cycle of rituximab</measure>
    <time_frame>1 treatment cycle (28 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in prostate-specific antigen (PSA)</measure>
    <time_frame>from Day 1 to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in peripheral blood B cell number</measure>
    <time_frame>from Day 1 to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum CXCL13 level</measure>
    <time_frame>from Day 1 to Day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab will be administered intravenously at a dose of 375 mg/m2 of body surface area once per week for 4 weeks (Days 1, 8, 15, and 22 of a 28-day cycle).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>Rituximab will be administered intravenously at a dose of 375 mg/m2 of body surface area once per week for 4 weeks (Days 1, 8, 15, and 22 of a 28-day cycle).</description>
    <arm_group_label>rituximab</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to understand and provide written informed consent.&#xD;
&#xD;
          -  Patient has EITHER:&#xD;
&#xD;
               -  A Kattan nomogram predicted probability of being disease free 5 years after&#xD;
                  surgery of &lt; 60%, OR&#xD;
&#xD;
               -  A Gleason sum ≥ 8.&#xD;
&#xD;
          -  Indicated for radical prostatectomy.&#xD;
&#xD;
        Note: candidates for radical prostatectomy are still eligible even if they have a history&#xD;
        of deep venous thrombosis, pulmonary embolism, and/or cerebrovascular accident or currently&#xD;
        requiring systemic anticoagulation.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (Appendix A).&#xD;
&#xD;
          -  Males aged ≥ 18 years.&#xD;
&#xD;
          -  Adequate organ function as defined below measured within 21 days of study entry:&#xD;
&#xD;
          -  Hematology:&#xD;
&#xD;
               -  Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L&#xD;
&#xD;
               -  Platelet count ≥ 100 x 109/L&#xD;
&#xD;
               -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
               -  White blood cell (WBC) count ≥ 3.0 x 109/L&#xD;
&#xD;
          -  Biochemistry:&#xD;
&#xD;
               -  Aspartate aminotransferase/serum glutamic-oxaloacetic transaminase (AST/SGOT) and&#xD;
                  alanine transaminase/serum glutamate pyruvate transaminase (ALT/SGPT) ≤ 2 x&#xD;
                  institution's upper limit of normal (ULN)&#xD;
&#xD;
               -  Total bilirubin &lt;1.5 times ULN&#xD;
&#xD;
               -  Serum creatinine and blood urea nitrogen (BUN)&lt;1.5 times ULN&#xD;
&#xD;
               -  Na, K Cl, carbon dioxide (CO2), Ca, phosphate (PO4) within institutional limits&#xD;
&#xD;
          -  Available prostate biopsy specimen which is evaluable for B lymphocyte count.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received prior treatment for prostatic adenocarcinoma including prior surgery&#xD;
             (excluding TURP), radiation therapy, or chemotherapy.&#xD;
&#xD;
          -  Current or past use of investigational agents within 4 weeks of study enrollment.&#xD;
&#xD;
          -  Evidence of metastatic disease on cross sectional imaging or bone scan.&#xD;
&#xD;
          -  History of hepatitis B or C, hepatitis immunodeficiency virus (HIV), tuberculosis or a&#xD;
             chronic infection of any type.&#xD;
&#xD;
          -  Positive test results for chronic hepatitis B infection (defined as positive HBsAg&#xD;
             serology).&#xD;
&#xD;
          -  Positive test results for hepatitis C (hepatitis C virus [HCV] antibody serology&#xD;
             testing).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Howell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moores UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0698</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>March 1, 2013</study_first_submitted>
  <study_first_submitted_qc>March 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2013</study_first_posted>
  <last_update_submitted>May 17, 2017</last_update_submitted>
  <last_update_submitted_qc>May 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Stephen Howell, M.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Prostate</keyword>
  <keyword>Cancer</keyword>
  <keyword>Castration-resistant</keyword>
  <keyword>Rituximab</keyword>
  <keyword>neoadjuvant</keyword>
  <keyword>Rituxan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

